HOT NEWS
Novartis
NovartisNovartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group's continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 97,000 full-time associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis RSS Channel

Title Filter     Display # 
# Article Title Hits
1 Novartis delivers strong financial performance in second quarter 875
2 Novartis gains new indication for Diovan®* for the treatment of children and adolescents 1295
3 Novartis receives approval in the European Union for Menveo® 1188
4 Novartis oral MS therapy FTY720 shows reduced risk of confirmed disability progression 1593
5 Novartis set to sustain its leading global position in oncology 2691
6 Novartis receives approval in the European Union for Onbrez® Breezhaler® 1710
7 Novartis receives regulatory approval in Germany for Celtura® 1064
8 Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China 1199
9 Novartis unveils Lab of Future concept to top European students at Biotechnology Leadership Camp (BioCamp) 1224
10 Afinitor® approved in EU as first treatment proven to benefit patients with advanced kidney cancer 2024
11 Novartis delivers strong operational performance in the first half of 2009 1254
12 Once-yearly Aclasta® approved in EU to treat osteoporosis 3794
13 Sandoz to acquire EBEWE Pharma specialty generics business 1701
14 Glivec® approved in EU as first post-surgery therapy 1696
15 Novartis expects strong operational performance in 2009 874
16 Glivec® recommended for use in Europe as first post-surgery treatment for gastrointestinal stromal tumors (GIST) 1663
17 Novartis gains worldwide rights to elinogrel, a Phase II anti-clotting compound 1285
18 Novartis increases dividend by 25% based on strong 2008 results 1180
19 Novartis launches Extavia®, the standard-of-care for relapsing forms of multiple sclerosis 1444
20 Four innovative Novartis medicines approved in Japan 1383
 
  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  Next 
  •  End 
  • »
Page 1 of 2
Bookmark and Share